omniture
logo
Search
科济生物医药（上海）有限公司
Media Room

Photo News

rss
CARsgen Therapeutics Announces 2026 Interim Results

CARsgen Therapeutics Announces 2026 Interim Results

2026-08-19 08:15 2685
CARsgen Therapeutics Announces 2025 Annual Results

CARsgen Therapeutics Announces 2025 Annual Results

2026-03-06 20:03 11601
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

2026-01-12 21:05 10200
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

2025-12-07 17:21 4532
CARsgen Therapeutics Announces 2025 Interim Results

CARsgen Therapeutics Announces 2025 Interim Results

2025-08-15 08:15 4186
CARsgen Announced 2024 Annual Results

CARsgen Announced 2024 Annual Results

2025-03-19 08:15 5049
CARsgen® Announces 2024 Interim Results

CARsgen® Announces 2024 Interim Results

2024-08-29 20:50 4802
CARsgen Announced 2023 Annual Results

CARsgen Announced 2023 Annual Results

2024-03-27 20:50 3551
CARsgen Announces Formation of its Clinical Advisory Board

CARsgen Announces Formation of its Clinical Advisory Board

2023-11-20 21:50 3669
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival

CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival

2023-10-12 20:50 2566
CARsgen Announced 2023 Interim Results

CARsgen Announced 2023 Interim Results

2023-08-22 19:30 4204
CARsgen Announced 2022 Annual Results and Business Updates

CARsgen Announced 2022 Annual Results and Business Updates

2023-03-22 20:50 3146
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

2022-10-31 21:30 3543
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

2022-08-24 20:50 3860
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

2022-08-18 20:50 2698
CARsgen Appoints Dr. Hua Jiang as Executive Director

CARsgen Appoints Dr. Hua Jiang as Executive Director

2022-08-02 20:50 3076
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

2022-04-07 23:42 3367
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

2022-03-23 20:50 2542
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

2022-03-23 20:50 4433
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

2022-01-17 21:50 3177